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Abstract:  Lysophosphatidic acid (LPA) is a bioactive phospholipid that stimulates cell proliferation and migration, and
protects cells from apoptosis.  It interacts with specific G protein-coupled transmembrane receptors.  Recently, frequent
mutations of the LPA receptor-1 (LPA1) gene were detected in rat lung adenocarcinomas induced by N-nitrosobis(2-
hydroxypropyl)amine (BHP).  In this study, to evaluate the involvement of other LPA receptor gene alterations during
lung carcinogenesis, we investigated mutations of the LPA2, LPA3, LPA4 and LPA5 genes in lung adenocarcinomas
induced by BHP in rats.  Fifteen male Wistar rats, 6 weeks of age, were given 2000 ppm BHP in their drinking water
for 12 weeks and then maintained without further treatment until sacrifice at 25 weeks, and 15 adenocarcinomas were
obtained.  Genomic DNAs were extracted from frozen tissues, and the LPA2, LPA3, LPA4 and LPA5 genes were
examined for mutations, using polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP)
analysis.  No mutations of LPA2, LPA3, LPA4 and LPA5 were detected in the 15 adenocarcinomas.  These results
suggest that alterations due to LPA2, LPA3, LPA4 and LPA5 gene mutations might not be involved in the development
of lung adenocarcinomas induced by BHP in rats.  (J Toxicol Pathol 2010; 23: 63–66)
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Introduction
Lung cancer is one of the most common human
malignancies, but the rate-limiting molecular events
involved in its development remain largely unknown.  The
experimental model that we have used in several of our
studies features the development of non-small cell lung
cancers in rats given N-nitrosobis(2-hydroxypropyl)amine
(BHP) in their drinking water, with high yields of
adenomatous lesions, including adenocarcinomas1,2.  As the
step by step development of lung malignancies is accessible
with this model, the molecular mechanisms involved can be
readily investigated.  Taking advantage of this model, we
have been able to accumulate data on genetic and epigenetic
alterations during carcinogenesis, including Ki-ras gene
mutations3, alterations in genes associated with transforming
growth factor-β signaling pathway4,5 and aberrant DNA
methylation patterns of E-cadherin, p16 and Tslc1 genes,
associated with reduced expressions6,7.
Lysophosphatidic acid (LPA) is a bioactive mediator
that induces diverse cellular effects, including regulation of
cell proliferation, differentiation, transcellular migration,
morphogenesis and protection from apoptosis8–13.  Since
LPA can induce cell proliferation, migration, invasion and
production of angiogenic factors in human ovarian cancer
cell lines, it has been suggested that LPA may play an
important role in the development of tumor cells9,10,14.  LPA
interacts with at least five G protein-coupled transmembrane
receptors, lysophosphatidic acid receptor-1 (LPA1), LPA2,
LPA3, LPA4 and LPA515–18.  LPA1 is ubiquitously
expressed in normal tissues, but the expressions of the other
LPA receptor subtypes are relatively restricted, suggesting
these receptors may have different biological functions in
regard to LPA15–18.  Aberrant expressions of LPA receptors
have been reported in human cancers, including ovarian,
colorectal and thyroid cancers, indicating that alterations of
LPA receptor expression might be important in the
malignant transformation of tumor cells as well as LPA per
se9,10,13,14,19.  Moreover, we detected that the 5’ upstream
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region of the LPA1 gene was highly methylated in rat tumor
cell lines, which showed undetectable LPA1 expression,
suggesting aberrant DNA methylation may be involved in
silencing of the LPA1 gene20.
Recently, we have also reported that LPA1 gene
mutations occurred in not only adenocarcinomas but also
adenomas during rat lung carcinogenesis induced by BHP21.
In the present study, to evaluate the involvement of other
LPA receptor gene alterations during lung carcinogenesis,
we investigated mutations of the LPA2, LPA3, LPA4 and
LPA5 genes in lung adenocarcinomas of rats.
A total of 18 male Wistar rats, at 5 weeks of age, were
purchased from Japan SLC Inc. (Shizuoka, Japan) and
housed 3–5 per cage in an air-conditioned room, with a
constant temperature of 25°C and a 12-h light-dark cycle.
Food and water were provided ad libitum throughout the
study.  After a one week acclimation period on a basal diet in
pellet form (CF-2 Diet; Clea Japan, Tokyo, Japan), fifteen
animals received drinking water containing BHP (Nacalai
Tesque, Inc., Kyoto, Japan) at a concentration of 2000 ppm
for 12 weeks; they received drinking water without BHP
thereafter.  In order to obtain normal lung tissue, three
animals were maintained free from carcinogen exposure
throughout the experimental period.
All rats were exsanguinated from the abdominal aorta
under light ether anesthesia 25 weeks after the beginning of
the experiment1,2.  The lungs were immediately excised and
grossly apparent tumors were dissected from their
surrounding tissue.  Samples were frozen in liquid nitrogen
and stored at –80°C until analysis.  Portions of the tumors
were fixed in 10% neutrally buffered formalin at 4°C,
routinely processed for hematoxylin and eosin staining, and
histopathologically evaluated according to diagnostic
criteria previously described1–3.  All experiments and
procedures carried out on the animals were approved by the
Animal Care Committee of Kinki University.  All the
samples were the same as those used in a previous study21.
Genomic DNA was extracted from frozen tissues of 15
adenocarcinomas and 3 normal lung tissues as described
previously6,7.  Polymerase chain reaction (PCR)-single
strand conformation polymorphism (SSCP) analysis was
conducted to look for mutations in the LPA2, LPA 3, LPA 4
and LPA 5 genes.  The primers used in the present study
were designed to amplify the open reading frames of the
LPA2, LPA3, LPA4 and LPA5 genes with intron sequences
flanking coding exons (NCBI accession numbers
NC_005115, NC_005101, NC_005120 and NC_005103,
respectively; Table1).  Briefly, PCR for SSCP analysis was
performed in 10 μl of reaction mixture containing 1 μM of
each primer, 200 μM of each dNTP, 1× PCR buffer (Applied
Biosystems Japan Ltd., Tokyo, Japan), 2.5 units of
AmpliTaq (Applied Biosystems Japan) and 0.5 μl of
extracted genomic DNA under the following reaction
conditions: primary denaturation for 2 min at 96°C followed
by 36 cycles of 15 s of denaturation at 96°C, 15 s of
annealing at 56–66°C and 30 s of extension at 72°C, and a
final extension period of 2 min at 72°C.  PCR products were
diluted with 10 μl of loading solution containing 90 %
formamide, 20 mM EDTA, 0.05% xylene cyanol and 0.05%
bromophenol blue.  Aliquots containing 6 μl of diluted
products were electrophoresed on polyacrylamide gels using
a GeneGel Excel 12.5/24 kit (GE Healthcare UK Ltd.,
Buckinghamshire, England) at 8, 15, 18 and 20°C for 90 min
at 15W, using a GenePhor Electrophoresis Unit (GE
Healthcare UK Ltd.).  After electrophoresis, the gels were
stained with a DNA Silver Staining kit (GE Healthcare UK
Ltd.)21.
There were a total of fifteen lung tumors, and all were
histologically well-differentiated adenocarcinomas.  Three
normal lung tissues obtained from untreated rats were used
as controls to eliminate the possibility of contamination with
macroscopically undetected cancerous tissue.
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Using primers to amplify coding regions of LPA2,
LPA3, LPA4 and LPA5, the PCR products showed clear
single bands in 1% agarose gels (data not shown).
Representative results of the PCR-SSCP analysis are shown
in Fig. 1.  No abnormal band shifts were detected in the 15
adenocarcinomas, indicative of no mutations in the LPA2,
LPA3, LPA4 and LPA5 genes.  We also confirmed by direct
nucleotide sequencing that all amplified PCR products
contained the normal LPA2, LPA3, LPA4 and LPA5
sequences (data not shown).
In a recent study, we reported that LPA1 gene
mutations were found in 2 out of 12 adenomas (16.7%) and
7 out of 17 adenocarcinomas (41.2%), which suggests that
mutations of the LPA1 gene may be involved in the
acquisition of growth advantage from adenomas to
adenocarcinomas in lung carcinogenesis induced in rats by
BHP21.  Moreover, we also detected frequent mutations of
the LPA1 gene in hepatocellular carcinomas induced by N-
nitrosodiethylamine in rats22.  Therefore, this evidence
suggests that the LPA1 gene is a target of mutations by
nitroso-compounds in the development of lung and liver
tumors in rats, but not the LPA2, LPA3, LPA4 and LPA5
genes.  Previously, we reported aberrant expressions of the
LPA1, LPA2 and LPA3 genes in lung adenocarcinomas
induced by BHP in rats23.  Although the expression levels of
the LPA4 and LPA5 genes have not yet been clarified, it
seems that aberrant expressions of LPA2, LPA3, LPA4 and
LPA5 may be involved in rat lung carcinogenesis rather than
mutational alterations.  We are currently investigating the
expression levels of the LPA4 and LPA5 genes in rat lung
adenocarcinomas induced by BHP.
In conclusion, the present study detected no mutations
of the LPA2, LPA3, LPA4 and LPA5 genes in rat lung
adenocarcinomas induced by BHP.  Recently, we reported
LPA1 gene mutations in pancreatic duct adenocarcinomas
induced by N-nitrosobis(2-oxopropyl)amine in hamsters24.
To better understand the involvement of LPA receptor genes
during carcinogenesis, we are currently investigating LPA2,
LPA3, LPA4 and LPA5 gene mutations in hamster
pancreatic duct adenocarcinomas.
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